Nulojix

Chemical Namebelatacept
Dosage FormInjection (intravenous; 250 mg)
Drug ClassSelective T-cell costimulation blockers
SystemMultiple
CompanyBristol Myers Squibb
Approval Year2011

Indication

  • Indicated in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids for prophylaxis of organ rejection in adult patients receiving a kidney transplant.
Last updated on 11/15/2022

More on this drug: Clinical Trials

Document TitleYearSource
Nulojix (belatacept) Prescribing Information.2021Bristol-Myers Squibb Company, Princeton, NJ